Highlights  First report of 17β-acetyl-testosterone-7-platinum(II) complexes (compounds 10a-f)  Compounds 10a, b and f exhibit IC50 and LC50 in the low micromolar range  Compounds 10a, b and f block the cell cycle progression in S-phase  Compounds 10a, b and f induce phosphorylation of H2AX into H2AX
Introduction
Prostate cancer is a major public health problem worldwide. In the United-States, prostate cancer is ranked first amongst all cancer cases diagnosed in men and it is the second most lethal cancer. It is estimated that in 2013, 238 590 new cases of prostate cancer will be diagnosed in the US and that 29 720 Americans will die from that disease [1] . Androgen receptor (AR) is a cytoplasmic receptor that mediates gene expression. AR is also a member of the superfamily of steroid and nuclear receptors [2] . In adult men, androgens and AR are responsible for secondary sexual characteristics such as spermatogenesis, muscle mass, bone mineral density, erythropoiesis and the maintenance of libido [3, 4] . AR activation by endogenous androgens such as testosterone (1, Fig. 1 ) and dihydrotestosterone (DHT, 2) leads to sequential conformations of the receptor (required by the dissociation of chaperone proteins), dimerization, phosphorylation and translocation into the nucleus for transcription of the target genes [2] . AR and endogenous androgens play key roles in the initiation of the differentiation, progression and the maintenance of prostate cancer [5] [6] [7] . (4), CDDP (5) , carboplatin (6) HE3235 (7) compounds assessed in this study (compounds 8a-f, 9a-f and 10a-f).
Anti-hormone therapies using either luteinizing hormone-releasing analogs (e.g. leuprolide [8] ), anti-androgens (bicalutamide (3) [9] , cyproterone acetate (4) [10] ) and orchiectomy are effective against prostate cancer at their early stages. However, it must be kept in mind that anti-hormone therapies exhibit several significant side effects such as incontinence, erectile dysfunction, depression, muscle loss, anemia, osteoporosis and many others [11] . Although many patients benefit from the therapy and experience prolonged remission, 10 to 20% of patients are still developing castration-resistant prostate cancer (CRPC) within 5 years of the follow-up and 84% of those CRPC are metastatic [12] . At this point, the first-line chemotherapy regimen approved by the FDA includes first docetaxel and prednisone for three weeks [13] . The positive response to the treatment does not exceed 6 month with a median survival time of 18.9 months [14] . The second-line chemotherapy involves several other antineoplastics such as abiraterone acetate, cabozantinib, ipilimumab, TAK-700 and their therapeutic combinations that are under clinical investigation to assess their clinical efficacy and potential benefits [15] . Among those, platinum(II)-based chemotherapeutics such as cisplatin (CDDP, 5) and carboplatin (6) are of growing interest [16] despite the belief that they exhibit only modest activity against prostate cancers and CRPC [17] . However, the clinical benefits achieved so far remains low and increasing the survival by only 3 to 6 months [15, 17] . Therefore, the development of more effective platinum(II)-based therapies to improve both life expectancy and the quality of life of CRPC patients is still urgently needed.
Although anti-hormone therapies are ineffective against CRPC, several groups have shown that ARs are still expressed [18] and they still play important roles in tumor growth of CRPC as demonstrated by the expression of the AR regulated gene, prostate-specific antigen (PSA) [5] . On the other hand, chemoresistance can also be related to multifactorial causes such as increased expression of AR, AR gene mutations and altered ligand specificity, downstream signaling receptor for androgens and other bypass pathways. The latter can result in activation of AR requiring very low androgen concentration, activation by ligands that are not normally agonistic or ligand-independent [19] [20] [21] .
In such a context, treatment of CRPC with androgen supplementation seems counterintuitive.
However, preclinical studies showed that testosterone inhibits tumor cell growth both in vitro [22] and in vivo [23] . Moreover, it has been shown that high-doses of exogenous testosterone can be safely administered to patients with CRPC [24, 25] . The authors have evidenced the antitumor activity of the treatment and the long-term stabilization of the disease in patients exhibiting low PSA concentrations. Another example of androgen supplementation approach is the use of HE3235 (7), a synthetic androgen analog. HE3235 exhibited a potent antiproliferative and proapoptotic activity both in vitro and in vivo [26, 27] . Moreover, phase I studies showed that it was safe and well tolerated [28] . Thus, androgen therapy targeting ARmediated signaling seems a possible and an innovative new approach for treatment of selected types of CRPC [29, 30] .
In the aim to improve the cytocidal activity, the selectivity and the biopharmaceutical properties of anticancer drugs toward prostate cancer tumors, we designed new combimolecules merging 17β-acetyl-testosterone and different new platinum(II) complexes to target simultaneously the AR-mediated signaling pathway and DNA. In this study, we described the design, the preparation and the biological evaluation of three series of combi-molecules namely: Boc amino acids, amino acids and platinum(II) complexes that are conjugated at position 7 of the 17β-acetyl-testosterone (17-acetyl-testosterone-7-Boc amino acids (compounds 8a-f), 17-acetyl-testosterone-7-amino acids (compounds 9a-f) and 17β-acetyltestosterone-7-platinum(II) complexes (compounds 10a-f), respectively). We assessed the antiproliferative activity of the Boc, amine and platinum(II) complex moieties, respectively on androgen-sensitive human prostate adenocarcinoma LNCaP cells and androgen-insensitive human prostate adenocarcinoma PC3 and DU145 cells and that in regard of the nature of the amino acid side-chain. The most potent combi-molecules were assessed also for: (1) antiproliferative activity on a panel of 8 cancer cell lines unrelated to prostate cancer comprising HT-1080, HT-29, M21, MCF-7, MDA-MB-231, MDA-MB-468, CEM and CEM-VLB cells, (2) effect on cell cycle progression, (3) potential induction of histone H2AX phosphorylation and (4) antitumoral activities and toxicity onto the chick chorioallantoic membrane (CAM) tumor assays.
Design and chemistry
First, 17β-acetyl-testosterone was selected as the carrier for combi-molecules based on its natural tropism for prostate tissue, to optimize the pharmacokinetics and the pharmacodynamics of testosterone towards AR and to activate AR signaling pathways.
Second, position 7 of testosterone is located away from the 3-carbonyl and 17-hydroxyl groups that are involved in key hydrogen interactions with AR. These two crucial groups must be free of steric hindrances to favor optimal interactions with AR and to trigger the signaling pathways. Finally, L-and D-2-pyridylalanine, L-and D-methionine, L-histidine and L-4thiazolylalanine amino acids were selected because they easily form platinum(II) complexes and that they are inexpensive templates to optimize our synthetic approaches [31, 32] . We also observed in our recent studies on estrogen combi-molecules that amino pyridine group easily form platinum(II) complexes and show interesting biological activities [33] [34] [35] [36] .
The methods used for the preparation of 17-acetyl-testosterone-7-Boc amino acids (compounds 8a-f), 17-acetyl-testosterone-7-amino acids (compounds 9a-f) and 17β-acetyltestosterone-7-platinum(II) complexes (compounds 10a-f) are described in Scheme 1.
Compound 11 was prepared in excellent yields as published elsewhere using the method described by Nickisch et al. [37] and Bastien et al. [38] [39] [40] [41] . Then, 17-acetyl-testosterone-7-Boc amino acids (compounds 8a-f) were obtained after treatment of compound 11 and the selected amino acid in the presence of cesium carbonate in methyl ethyl ketone. Afterwards, 17-acetyl-testosterone-7-amino acids (compounds 9a-f) were achieved by treatment of compounds 8a-f with trifluoroacetic acid in methylene chloride. Finally, compounds 9a-f were treated with potassium tetrachloroplatinate(II) in a mixture of dimethylformamide and water to afford 17β-acetyl-testosterone-7-platinum(II) complexes (compounds 10a-f). MTT cell proliferation assay with minor modifications [42, 43] . The results are summarized in Table 1 and show antiproliferative activity (IC50) and the median lethal concentration (LC50) of 8a-f, 9a-f and 10a-f. IC50 is defined, as the concentration of drug inhibiting cell growth by 50% and the LC50 is concentration required to kill 50% of the cells. CDDP was used as positive control. Median lethal concentration (LC50) is the concentration required to kill 50% of the cells.
The antiproliferative activity of all three series of compounds was slightly higher on PC3 cells followed by LNCaP and DU145 cells. The antiproliferative activity of 17-acetyltestosterone-7-Boc amino acids (compounds 8a-f) and 17-acetyl-testosterone-7-amino acids (compounds 9a-f) were evaluated to assess the contribution of the platinum complex to the cytocidal activity. Compounds 8a-f and 9a-f were cytostatic and exhibiting IC50 between 12 and > 100 M while their LC50 were higher than 100 µM. Boc and amine series were clearly less active than their platinum complex counterparts showing IC50 in the low M range (1.4-28 M) indicating that the platinum complex moiety is crucial for the activity.
Interestingly, the stereochemistry of the amino acids used has minor effects on the activity as indicating that 10a, b and f were much more cytocidal than CDDP. On one hand, compound 10f bearing a thiazolyl moiety exhibited the highest antiproliferative activity with IC50 of 1.8, 1.4 and 1.9 µM on LNCaP, PC3 and DU145 cells which are up to five times more potent than CDDP alone that exhibited IC50 of 6.7, 7.4 and 2.1 µM, respectively. On the other hand, the LC50 of 10f on the same cell lines were from 9 to over 38-times more potent than CDDP (4.7, 2.6 and 6.4 μM for 10f vs. 44, >100 and >100 µM for CDDP, respectively). Moreover, the general aspects of the antiproliferative curves for 17β-acetyl-testosterone-7-platinum(II) complexes and CDDP are quite different. For example, when the concentration of CDDP alone increases, the cell growth decreases slowly while when using 17β-acetyl-testosterone-7-platinum(II) complexes the cell growth decreases dramatically within a short range of concentrations suggesting that CDDP and 17β-acetyl-testosterone-7-platinum(II) complexes do not act completely through the same mechanism of action. overexpressing P-glycoprotein [52] , which is responsible for the cellular efflux of several anticancer drugs such as doxorubicin, paclitaxel, and vinblastine. In addition P-glycoprotein is part of a potent mechanism of resistance encountered in clinical settings [53] [54] [55] . CDDP, colchicine and vinblastine are used as positive controls. Interestingly, the IC50 of 17β-acetyl-testosterone-7-platinum(II) complexes were higher than CDDP alone on MDA-MB-468, CEM and CEM-VLB cells while they were lower on other cancer cell lines. CEM-VLB cells exhibited low resistance to 10a, b and f (5.7-, 6.7-and 7.2-fold) which are more than 10-times lower than for colchicine (87-fold) and several logs lower than vinblastine (980-fold) while CDDP was clearly unaffected by the overexpression of Pglycoprotein. This suggests that overexpression of P-glycoprotein does not affect the antiproliferative activity of 17β-acetyl-testosterone-7-platinum(II) complexes. In addition, except for CEM-VLB cells, the LC50 of 17β-acetyl-testosterone-7-platinum(II) complexes
10a, b and f (0.64-4.0 µM) were several times lower than that of CDDP (1.3-50 µM), which were similar to the results obtain on prostate cancer cell lines. However, the IC50 and the LC50 of the most potent 17β-acetyl-testosterone-7-platinum(II) complexes 10a, b and f were several times higher than colchicine and vinblastine. Table 4 shows the percentage of PC3 cells that are in Sub-G1, G0/G1, S and G2/M phases, 
Effect on Cell Cycle Progression

Phosphorylation of histone H2AX
DNA replication is the main event occurring during the S-phase and platinum(II)-based anticancer agents are well known to form reactive species such as cationic aqua ligand that bind to DNA, resulting in intrastrand and interstrand cross-links [56, 57] , triggering the formation of DNA single-and double-strand breaks that lead to apoptosis [58, 59] . Moreover, phosphorylation of Ser-139 at the C-terminus of histone H2AX (H2AX) occurs upon induction of DNA double-strand breaks [60, 61] . Consequently, we used the phosphorylation of H2AX into of H2AX to assess the effect of the platinum complex moiety in the mechanism of action and in the activity of compounds 10a, b and f. As depicted in Table 4 , compounds 10a, b and f and CDDP induced H2AX phosphorylation in PC3 cells. γH2AX
was detected as nuclear red spots in nuclei stained in blue by 4′,6-diamidino-2-phenylindole (DAPI). As shown in Table 4 , compounds 10a, b and f induced lower level of γH2AX than CDDP and therefore less double-strand breaks.
The induction of DNA double-strand breaks confirmed by the phosphorylation of H2AX (γH2AX) explains at least in part the mechanism of action of 17β-acetyl-testosterone-7platinum(II) complexes. In fact, the phosphorylation of H2AX into γH2AX does not correlate to the cytotoxicity of CDDP and 17β-acetyl-testosterone-7-platinum(II) complexes; 17βacetyl-testosterone-7-platinum(II) complexes induced a lower number of double-strand breaks than CDDP while they were significantly more cytotoxic than CDDP. This suggests that the platinum(II) complexes are responsible for only a portion of the cytocidal activity.
Research is in progress to determine the contribution of each constituent of the combimolecules (testosterone and the various platinum complexes) to the cytocidal activity.
Chick chorioallantoic membrane (CAM) tumor assay
The As depicted in Fig. 2, compounds 10a , b and f significantly inhibited tumor growth by 33, 21 and 32%, respectively and exhibited toxicity in 18, 29, and 21% of the chick embryos, respectively. CDDP inhibited tumor growth by 50% and exhibited toxicity in 5% of the chick embryos. Thus, we conclude that the excipient is not toxic for the embryos, the compounds 
Conclusion
In this study, we designed, prepared and characterized six new combi-molecules The cells were maintained at 37 °C in a moisture saturated atmosphere containing 5% CO2.
Antiproliferative activity assay
The antiproliferative activity of compounds 8a-f, 9a-f, 10a-f, CDDP, colchicine and vinblastine was assessed using the MTT assay [42, 43] . Briefly, the 96-well microtiter plates were seeded with 75 μL of a tumor cells in suspension (for LNCaP, 12 000; PC3, 6 000; DU 145, 6 000; HT-1080, 2 500; HT-29, 3 000; M21, 3 000; MCF-7, 3 000; MDA-MB-231, 5 000; MDA-MB-468, 5 000; CEM, 10 000; CEM-VLB, 10 000) in medium. Plates were incubated at 37 °C, 5% CO2 for 24 h. Readings obtained from treated cells were compared with measurements from control cells plates fixed on the treatment day, and the percentage of cell growth inhibition was then calculated for each drug. The experiments were performed at least twice in triplicate. The assays were considered valid when the coefficient of variation for a given set of conditions and within the same experiment was < 10%.
Cell Cycle Analysis.
PC3 cells (2.5 × 10 5 ) were seeded into six-well plates and incubated for 24 h. Cells were then incubated with the test compound at 1.5 and 3-times their respective IC50 for 24 h at 37 °C.
The control solution consisted of DMF dissolved in culture medium at 0.1% v/v. After incubation, the cells were trypsinized, washed with PBS and resuspended in 250 μL of PBS.
Cells were fixed by the addition of 750 μL of ice-cold EtOH and stored at -20 °C until analysis. Prior to FACS, the cells were washed with PBS and resuspended in 1 mL of PBS containing 2 μg/mL of 4',6-diamidino-2-phenylindole (DAPI, Sigma, Oakville, Ontario, Canada). Fixed cell suspensions were incubated on ice for 1 h, and the cell cycle distribution was then analyzed using a BD SORP LSR II cytometer (BD Biosciences, Franklin Lakes, NJ).
Immunofluorescence
Cover slides (22 mm × 22 mm) sterilized with 70% (v/v) EtOH were placed in six-well plates.
To promote cell adhesion, cover slides were treated with 1. 
CAM Tumor Assay.
Human HT-1080 fibrosarcoma cells were used to assess the antitumoral activity of compound 10a, b, and f in the CAM assay [63, 65, 66] . Briefly, fertilized chicken eggs purchased from Couvoirs Victoriaville (Victoriaville, Québec, Canada) were incubated for 10 days in a Pro-FI egg incubator fitted with an automatic egg turner before being transferred to a Roll-X static incubator for the rest of the incubation time (incubators were purchased from Lyon Electric, Chula Vista, San Diego, CA). The eggs were kept at 37 °C in a 60% humidity atmosphere for the entire incubation period. On day 10, by use of a hobby drill (Dremel, Racine, WI), a hole was drilled on the side of the egg and a negative pressure was applied to create a new air sac.
A window was opened on this new air sac and was covered with transparent adhesive tape to prevent contamination. A freshly prepared cell suspension (40 μL) of HT-1080 (3.5 x 10 5 cells/egg) cells in the culture media was applied directly onto the freshly exposed CAM tissue through the window. On day 11, the drugs dissolved in DMF were extemporaneously diluted in the excipient (Cremophor™/ethanol 99%/PBS, 6.25/6.25/87.5 v/v). The concentration of DMF in the excipient was kept at 0.3% to avoid any potential toxicity. Forty µg for 17βacetyl-testosterone-7-platinum(II) complexes and 10 µg for CDDP dissolved in 100 μL of excipient were injected iv into 10-12 eggs. The eggs were incubated until day-17, at which time the embryos were euthanized at 4 °C followed by decapitation. Tumors were collected, and the tumor-wet weights were recorded. The number of dead embryos and signs of toxicity from the different groups were recorded.
Chemistry
Proton NMR spectra were recorded on a 
5.5
General procedure for the synthesis of platinum(II) complex conjugates at position 7 of 17β-acetyl-testosterone (17β-acetyl-testosterone-7-platinum(II) complexes 10a-f).
To a solution of the amino acid (compounds 9a-f, 1.0 eq., 0.10 mmol) in DMF (3 mL) at room temperature was added potassium tetrachloroplatinate(II) (1.5 eq., 0.15 mmol) dissolved in water (1.5 mL). After 5 days of stirring in darkness at room temperature, a saturated KCl solution (4 mL) was added followed by solid KCl (0.5 g). The mixture was vigorously stirred for 30 min. and the suspension was then filtered, washed with water (15 mL) and dried under vacuum. The crude compound was purified by flash chromatography on silica gel to afford cis-dichloroplatinum(II) complexes (compounds 10a-f). 
